532 related articles for article (PubMed ID: 29017563)
1. Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis.
Wilson FR; Coombes ME; Wylie Q; Yurchenko M; Brezden-Masley C; Hutton B; Skidmore B; Cameron C
Syst Rev; 2017 Oct; 6(1):196. PubMed ID: 29017563
[TBL] [Abstract][Full Text] [Related]
2. Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis.
Wilson FR; Coombes ME; Brezden-Masley C; Yurchenko M; Wylie Q; Douma R; Varu A; Hutton B; Skidmore B; Cameron C
Syst Rev; 2018 Nov; 7(1):191. PubMed ID: 30428932
[TBL] [Abstract][Full Text] [Related]
3. NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer.
Korner EJ; Morris A; Allen IE; Hurvitz S; Beattie MS; Kalesan B
Syst Rev; 2015 Oct; 4():133. PubMed ID: 26428301
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
Xu ZQ; Zhang Y; Li N; Liu PJ; Gao L; Gao X; Tie XJ
BMJ Open; 2017 Mar; 7(3):e013053. PubMed ID: 28289045
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy regimens in treatment of breast cancer: a systematic review and network meta-analysis protocol.
Pathak M; Dwivedi SN; Deo SVS; Thakur B; Sreenivas V; Rath GK
Syst Rev; 2018 Jun; 7(1):89. PubMed ID: 29945652
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.
Liu T; Liu D; Jin Y; Dong M
Immunopharmacol Immunotoxicol; 2022 Dec; 44(6):809-815. PubMed ID: 35708278
[TBL] [Abstract][Full Text] [Related]
7. Clinical therapeutic effects of trastuzumab in HER2-positive breast cancer patients: A protocol for systematic review and meta-analysis.
Tong C; Wang C; Yang K
Medicine (Baltimore); 2021 Apr; 100(17):e25685. PubMed ID: 33907141
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis.
Shen Y; Fujii T; Ueno NT; Tripathy D; Fu N; Zhou H; Ning J; Xiao L
Breast Cancer Res Treat; 2019 Jan; 173(1):1-9. PubMed ID: 30242579
[TBL] [Abstract][Full Text] [Related]
9. Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials.
Niraula S; Gyawali B
Breast Cancer Res Treat; 2019 Jan; 173(1):103-109. PubMed ID: 30238273
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
.
Madden R; Kosari S; Peterson GM; Bagheri N; Thomas J
Int J Clin Pharmacol Ther; 2018 Feb; 56(2):72-80. PubMed ID: 29231164
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
Kawalec P; Łopuch S; Mikrut A
Clin Breast Cancer; 2015 Apr; 15(2):90-100.e1. PubMed ID: 25441421
[TBL] [Abstract][Full Text] [Related]
12. Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort.
Daniels B; Lord SJ; Kiely BE; Houssami N; Haywood P; Lu CY; Ward RL; Pearson SA;
BMJ Open; 2017 Jan; 7(1):e014439. PubMed ID: 28119394
[TBL] [Abstract][Full Text] [Related]
13. Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials.
Hu Q; Wang X; Chen Y; Li X; Luo T; Cao D
BMJ Open; 2020 Nov; 10(11):e035802. PubMed ID: 33444169
[TBL] [Abstract][Full Text] [Related]
14. Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
.
Tian T; Ye J; Zhou S
Int J Clin Pharmacol Ther; 2017 Sep; 55(9):720-727. PubMed ID: 28737130
[TBL] [Abstract][Full Text] [Related]
15. Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials.
Chen L; Zhou W; Hu X; Yi M; Ye C; Yao G
Cancer Treat Rev; 2019 May; 75():12-19. PubMed ID: 30856373
[TBL] [Abstract][Full Text] [Related]
16. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Baselga J
Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Therapy for HER2-positive Breast Cancer.
Wuerstlein R; Harbeck N
Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
[TBL] [Abstract][Full Text] [Related]
18. One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.
Inno A; Barni S; Ghidini A; Zaniboni A; Petrelli F
Breast Cancer Res Treat; 2019 Jan; 173(2):247-254. PubMed ID: 30317424
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of first-line therapy in patients with HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials.
Wang J; Yu Y; Lin Q; Zhang J; Song C
J Cancer Res Clin Oncol; 2024 Jan; 150(1):21. PubMed ID: 38244085
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of efficacy of trastuzumab in adjuvant treatment of HER 2 positive early breast cancer - single institution experience.
Ban M; Viculin J; Tomic S; Capkun V; Strikic A; Mise BP; Utrobicic I; Vrdoljak E
Neoplasma; 2016; 63(5):761-7. PubMed ID: 27468880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
